Document is current
Any future updates will be listed below
-
Authors
Itagi, Pushpa
Schuster, Samantha L.
Arora, Sonali https://orcid.org/0000-0002-6661-3024
Persse, Thomas W.
Waters, Jennifer A.
Yang, Michael
Min, Alan
Chandra, Pooja https://orcid.org/0009-0001-6130-8792
Adil, Mohamed
Galipeau, Patricia C. https://orcid.org/0000-0001-7961-7430
Rudoy, Dmytro
Kreitman, Allie S. https://orcid.org/0000-0002-0390-5425
Lin, Yixin https://orcid.org/0009-0009-7449-3155
Ko, Minjeong
Sayar, Erolcan https://orcid.org/0000-0002-3922-5683
Patton, Robert D. https://orcid.org/0000-0003-2159-1199
Kollath, Lori
Meis, Abby https://orcid.org/0009-0004-2632-2603
Lindergren, Samuel
Ji, Nathan https://orcid.org/0009-0001-7757-370X
Ali, Khursheed https://orcid.org/0000-0002-1578-1781
Venkatesh, Hrishi
Wladyka, Cynthia L.
McDeed, A. Patrick
Mills, Claire B.
Vashisth, Manasvita
Kim, Jin Yeong
Nadal, Rosa
Hawley, Jessica E.
Yezefski, Todd A. https://orcid.org/0000-0003-2518-1680
Psutka, Sarah P. https://orcid.org/0000-0002-4207-7490
Gore, John L.
Lin, Daniel W.
Nelson, Peter S. https://orcid.org/0000-0002-5451-5726
Cheng, Heather H.
Schweizer, Michael T.
Fong, Lawrence https://orcid.org/0000-0002-6428-428X
Lee, John K. https://orcid.org/0000-0002-6570-2180
Yu, Evan Y.
Corey, Eva https://orcid.org/0000-0002-9244-3807
Morrissey, Colm
Grivas, Petros https://orcid.org/0000-0003-3965-3394
Montgomery, Robert B.
Wright, Jonathan L.
Haffner, Michael C.
Vakar-Lopez, Funda
Mian, Omar Y. https://orcid.org/0000-0002-8133-8120
Lam, Hung-Ming https://orcid.org/0000-0001-8921-6091
Hsieh, Andrew C. https://orcid.org/0000-0002-0897-1050
Ha, Gavin https://orcid.org/0000-0001-7578-7272
- License Information
-
More Information
Article History
Received: 16 July 2025
Accepted: 12 August 2026
First Online: 16 September 2026
Ethics
Competing interests: G.H. receives research support from Pfizer and consults with Quest Diagnostics; all activities unrelated to this work. A.C.H. is a consultant to the SAB of Interdict Bio; all activities unrelated to this work. C.B.M. has received consulting fees and travel support from Illumina unrelated to the current work. C.M. has received research funding from Genentech, Astra Zeneca, Janssen and Novartis, unrelated to the current work. E.C. served as a paid consultant to DotQuant and received Institutional sponsored research funding unrelated to this work from Astra Zeneca, AbbVie, Gilead, Sanofi, Zenith Epigenetics, Bayer Pharmaceuticals, Forma Therapeutics, Genentech, GSK, Janssen Research, Kronos Bio, Foghorn Therapeutics, K36 Therapeutics, BiondlessBio, and MacroGenics. E.Y.Y. has received consulting from Astellas, Johnson & Johnson, AZ, Tolmar, Merck, Bayer, Oncternal, Lantheus, Novartis, Samsung; and has received research funding to the institution provided by Dendreon, Merck, SeaGen, Blue Earth, Bayer, Lantheus, and Tyra. J.L.W. has received research support from Merck, Seagen, Pacific Edge, and Veracyte. J.K.L. serves as a research consultant for Lyell Immunopharma and Xilio Therapeutics; is a CMO and serves on the scientific advisory board for PromiCell Therapeutics. L.F. received research support from Abbvie, Merck, and Roche/Genentech; and has served on scientific advisory boards for Abbvie, Actym, Bioatla, Boehringer Ingelheim, Bristol Myer Squibb, Daiichi Sankyo, Immunogenesis, Innovent, Merck, Nutcracker, RAPT, Senti, Sutro, and Roche/Genentech. M.C.H. consults or has received honoraria from Pfizer and Astra Zeneca and has received research funding from Merck, Novartis, Genentech, Promicell and Bristol Myers Squibb. M.T.S. consults or has received honoraria from JNJ, Pfizer, Daiichi Sankyo, K36 Therapeutics and Bayer; and has received research support to his institution from Novartis, Zenith Epigenetics, BMS, merck, Epigenetix, Xencor, Ambrx, Oric Pharmaceuticals, AZ, Lightspeed and Kyntra. O.Y.M. consults with Veracyte, RiboX Therapeutics, and Electa; all activities unrelated to this work. P.S.N. served as a paid consultant to AstraZeneca, Genentech, and Pfizer and received research support from Janssen for work unrelated to the current study. P.G., for the past 2 years, has consulted with MSD, Bristol Myers Squibb, AstraZeneca, EMD Serono, Pfizer, Janssen, Roche, Astellas Pharma, Gilead Sciences, AbbVie, Bicycle Therapeutics, Replimune, Daiichi Sankyo, Foundation Medicine, Eli Lilly, Urogen, Tyra Biosciences, Natera, Ottimo Pharma, Bayer; and received research funding from MSD, EMD Serono, Gilead Sciences, Acrivon Therapeutics, ALX Oncology, Genentech (paid to institution). S.P.P. consults with J&J, CG Oncology, and Merck. T.A.Y. consults with Fennec, and Dendreon.
